BRPI0508771A - indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos - Google Patents
indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmosInfo
- Publication number
- BRPI0508771A BRPI0508771A BRPI0508771-6A BRPI0508771A BRPI0508771A BR PI0508771 A BRPI0508771 A BR PI0508771A BR PI0508771 A BRPI0508771 A BR PI0508771A BR PI0508771 A BRPI0508771 A BR PI0508771A
- Authority
- BR
- Brazil
- Prior art keywords
- indazoles
- benzothiazoles
- preparation
- compounds
- nach
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
INDAZóIS, BENZOTIAZóIS, BENZOISOTIAZóIS, BENZISOXAZóIS, E A PREPARAçãO E USOS DOS MESMOS. A presente invenção refere-se de maneira geral ao campo dos ligandos para os receptores de acetil colina nicotínicos (receptores de nACh), à ativação dos receptores de nACh, e a tratamento das condições de doenças associadas com os receptores de acetil colina nicotínica defeituosos ou funcionando mal, especialmente do cérebro. Adicionalmente, a presente invenção refere-se a novos compostos (por exemplo, indazóis e benzotiazóis), que agem como ligandos para o subtipo do receptor de 7<244> nACh, aos métodos de preparação de tais compostos, às composições que contêm tais compostos, e aos métodos de uso dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55595104P | 2004-03-25 | 2004-03-25 | |
US61603304P | 2004-10-06 | 2004-10-06 | |
PCT/US2005/010120 WO2005092890A2 (en) | 2004-03-25 | 2005-03-25 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508771A true BRPI0508771A (pt) | 2007-08-14 |
Family
ID=34968660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508771-6A BRPI0508771A (pt) | 2004-03-25 | 2005-03-25 | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos |
Country Status (18)
Country | Link |
---|---|
US (4) | US20050234095A1 (pt) |
EP (2) | EP1735306A2 (pt) |
JP (2) | JP4995075B2 (pt) |
KR (1) | KR101176670B1 (pt) |
CN (1) | CN103724343A (pt) |
AU (1) | AU2005227324A1 (pt) |
BR (1) | BRPI0508771A (pt) |
CA (1) | CA2560741C (pt) |
CR (2) | CR8711A (pt) |
EC (1) | ECSP066951A (pt) |
IL (2) | IL178188A (pt) |
MA (1) | MA28972B1 (pt) |
MX (1) | MXPA06010852A (pt) |
NO (1) | NO20064826L (pt) |
NZ (1) | NZ550534A (pt) |
RU (1) | RU2417225C2 (pt) |
SG (1) | SG165199A1 (pt) |
WO (1) | WO2005092890A2 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
EP1742944B1 (en) * | 2004-04-22 | 2010-11-10 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
AU2005319248A1 (en) * | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
BRPI0619672A2 (pt) * | 2005-11-09 | 2011-10-11 | Memory Pharm Corp | composto, composição farmacêutica, e, uso de um composto |
CA2654098A1 (en) * | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
JP2010531871A (ja) | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | 3−アザ−ビシクロ[3.3.0]オクタン化合物 |
BRPI0814593A2 (pt) | 2007-07-27 | 2015-01-20 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém e uso do composto. |
NZ585298A (en) * | 2007-11-16 | 2012-08-31 | Rigel Pharmaceuticals Inc | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
MX2010009462A (es) * | 2008-02-29 | 2010-09-24 | Pfizer | Derivados de indazol. |
WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
KR101098335B1 (ko) * | 2008-07-18 | 2011-12-26 | 성균관대학교산학협력단 | 신코나 기재 이작용성 유기 촉매 및 이를 이용한 메소-고리산무수물의 비대칭 고리 열림 반응을 통한 키랄성헤미에스터의 제조방법 |
MX2011003429A (es) | 2008-10-13 | 2011-05-02 | Hoffmann La Roche | Metodo libre de diazonio para fabricar un compuesto intermedio de indazol en la sintesis de las amidas del acido 5-(trifluorometoxi)-1h-3-indazolcarboxilico biciclico. |
PL2540297T3 (pl) | 2008-11-19 | 2015-12-31 | Forum Pharmaceuticals Inc | Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami |
DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
EP3305073B1 (en) | 2009-12-21 | 2019-05-15 | Samumed, LLC | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US20110172428A1 (en) | 2010-01-12 | 2011-07-14 | Shan-Ming Kuang | Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt |
US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
US8242276B2 (en) | 2010-06-30 | 2012-08-14 | Hoffmann-La Roche Inc. | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt |
CN103260619A (zh) | 2010-07-26 | 2013-08-21 | 英维沃医药有限公司 | 利用某些α-7烟酸受体激动剂与乙酰胆碱酯酶抑制剂的组合治疗认知障碍 |
KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
PE20141678A1 (es) | 2011-09-14 | 2014-11-21 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina |
US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
ES2752192T3 (es) | 2012-05-04 | 2020-04-03 | Samumed Llc | 1H-pirazolo [3,4-b]piridinas y usos terapéuticos de las mismas |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
JOP20130213B1 (ar) * | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
KR102226489B1 (ko) * | 2012-07-27 | 2021-03-11 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
MX370487B (es) | 2013-01-08 | 2019-12-16 | Samumed Llc | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
US9981928B2 (en) | 2013-06-20 | 2018-05-29 | Bayer Cropscience Aktiengesellschaft | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides |
SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
KR101731624B1 (ko) * | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
PL3201203T3 (pl) | 2014-09-29 | 2021-11-22 | Takeda Pharmaceutical Company Limited | Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu |
JP6612874B2 (ja) | 2014-12-16 | 2019-11-27 | アクソファント サイエンシーズ ゲーエムベーハー | α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
CN104628648A (zh) * | 2015-01-22 | 2015-05-20 | 湖南华腾制药有限公司 | 一种吲唑衍生物的制备方法 |
CA2988968A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
EP3334740A4 (en) * | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
BR112018009252A2 (pt) | 2015-11-06 | 2018-11-06 | Samumed Llc | tratamento da osteoartrite |
SI3464285T1 (sl) | 2016-06-01 | 2023-02-28 | Biosplice Therapeutics, Inc. | Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida |
AU2017345699A1 (en) | 2016-10-21 | 2019-05-16 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors |
WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
AU2018208458B2 (en) | 2017-01-10 | 2020-07-16 | ETH Zürich | Cell-protective compounds and their use |
EP3755696B1 (en) | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
AU2019234858A1 (en) * | 2018-03-14 | 2020-10-01 | Aerie Pharmaceuticals, Inc. | Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds |
EP3543231A1 (en) * | 2018-03-19 | 2019-09-25 | ETH Zurich | Compounds for treating cns- and neurodegenerative diseases |
KR102650856B1 (ko) * | 2019-12-16 | 2024-03-25 | 한국화학연구원 | 신규한 인다졸 유도체 및 이의 용도 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL59004A0 (en) | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
FI74707C (fi) * | 1982-06-29 | 1988-03-10 | Sandoz Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror. |
JPS5936675A (ja) * | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
FR2548666A1 (fr) | 1983-07-08 | 1985-01-11 | Delalande Sa | Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique |
DE3429830A1 (de) | 1983-08-26 | 1985-03-07 | Sandoz-Patent-GmbH, 7850 Lörrach | Automatische carbonsaeure- und sulfonsaeureester oder -amide |
US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
GB8623142D0 (en) | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
EP0200444B1 (en) * | 1985-04-27 | 1992-11-11 | Beecham Group Plc | Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity |
US4937247A (en) * | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
GB8518658D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Medicaments |
US5204356A (en) * | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
GB8520616D0 (en) * | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
IN166416B (pt) * | 1985-09-18 | 1990-05-05 | Pfizer | |
US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
HU895334D0 (en) * | 1986-07-30 | 1990-01-28 | Sandoz Ag | Process for the preparation of nasal pharmaceutical compositions |
GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
DE3872872T2 (de) * | 1987-11-14 | 1993-02-04 | Beecham Group Plc | 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. |
US4950759A (en) * | 1988-07-07 | 1990-08-21 | Duphar International Research B.V. | Substituted 1,7-annelated 1H-indazoles |
US4895943A (en) * | 1988-10-25 | 1990-01-23 | Pfizer Inc. | Preparation of 1,4-diazabicyclo(3.2.2)nonane |
EP0377238A1 (en) | 1988-12-22 | 1990-07-11 | Duphar International Research B.V | New annelated indolo (3,2-c)-lactams |
US5223625A (en) * | 1988-12-22 | 1993-06-29 | Duphar International Research B.V. | Annelated indolo [3,2,-C]lactams |
AU5650890A (en) | 1989-05-24 | 1990-12-18 | Nippon Shinyaku Co. Ltd. | Indole derivatives and medicine |
US5446050A (en) * | 1989-11-17 | 1995-08-29 | Pfizer Inc. | Azabicyclo amides and esters as 5-HT3 receptor antagonists |
GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
US5098889A (en) * | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
US5192770A (en) * | 1990-12-07 | 1993-03-09 | Syntex (U.S.A.) Inc. | Serotonergic alpha-oxoacetamides |
HU211081B (en) * | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
AU1161292A (en) | 1991-01-09 | 1992-08-17 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
KR0137003B1 (ko) | 1991-03-01 | 1998-04-25 | 카렌 에이. 홀브루크 | 신경계 퇴행성 질환치료용 니코틴 아날로그의 용도 |
GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
US5273972A (en) * | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
EP0659078B1 (en) | 1992-08-31 | 2003-01-15 | University Of Florida Research Foundation, Inc. | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
US5679673A (en) * | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
IT1256623B (it) * | 1992-12-04 | 1995-12-12 | Federico Arcamone | Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche |
GB9226573D0 (en) | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
IL119819A (en) | 1995-12-21 | 2004-07-25 | Syngenta Participations Ag | Processes for the preparation of derivatives of acid 3 - amino - 2 - Mercaptobenzoic, their use in the preparation of microbial and plant-killing agents and a number of such new compounds |
SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
US5714946A (en) * | 1996-04-26 | 1998-02-03 | Caterpillar Inc. | Apparatus for communicating with a machine when the machine ignition is turned off |
US6624173B1 (en) * | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
KR100247563B1 (ko) | 1997-07-16 | 2000-04-01 | 박영구 | 키랄3,4-에폭시부티르산및이의염의제조방법 |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
JP4637351B2 (ja) | 1998-06-01 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 神経変性疾患の処置法 |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
US6313110B1 (en) | 1999-06-02 | 2001-11-06 | Dupont Pharmaceuticals Company | Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor |
US6599917B1 (en) | 1999-09-28 | 2003-07-29 | Eisai Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
SE9903997D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
DE60109924T2 (de) | 2000-05-25 | 2006-02-09 | Targacept, Inc. | Heteroaryldiazabicycloalkane als liganden für den nikotinischen acetylcholin-rezeptor |
FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1−アザビシクロアルカン化合物およびその医薬用途 |
US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
WO2002015662A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
JP2002100858A (ja) * | 2000-09-25 | 2002-04-05 | Matsushita Electric Ind Co Ltd | フラックス塗布方法、フローはんだ付け方法およびこれらのための装置ならびに電子回路基板 |
AU2002211176A1 (en) | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
ES2275808T3 (es) * | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
EP1397365B1 (en) | 2001-06-01 | 2005-02-16 | NeuroSearch A/S | Heteroaryl-diazabicyclo-alkanes as cns-modulators |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
EP1425286B1 (en) | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
IL160884A0 (en) * | 2001-10-02 | 2004-08-31 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
MXPA04003986A (es) | 2001-10-26 | 2004-07-23 | Upjohn Co | Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr. |
US6849620B2 (en) * | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
BR0214016A (pt) | 2001-11-09 | 2004-10-13 | Upjohn Co | Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr |
DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10162375A1 (de) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
DE10305922A1 (de) * | 2002-06-10 | 2004-03-04 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
MXPA04008152A (es) | 2002-02-19 | 2005-09-08 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
EP1478646A1 (en) * | 2002-02-20 | 2004-11-24 | PHARMACIA & UPJOHN COMPANY | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
ES2197001B1 (es) | 2002-03-26 | 2004-11-16 | Laboratorios Vita, S.A. | Procedimiento de obtencion de un compuesto farmaceuticamente activo. |
AU2003222738B2 (en) | 2002-05-07 | 2009-09-17 | Neurosearch A/S | Novel azacyclic ethynyl derivatives |
DE60307102T2 (de) | 2002-05-30 | 2006-12-07 | Neurosearch A/S | 3-substituierte chinuclidine und ihre verwendung |
CA2488761C (en) * | 2002-06-10 | 2011-05-31 | Bayer Healthcare Ag | 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors |
JP2004029050A (ja) * | 2002-06-17 | 2004-01-29 | Sony Corp | 光記録媒体再生用対物レンズおよび光記録媒体再生装置 |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
AU2003255767A1 (en) | 2002-08-10 | 2004-02-25 | Astex Technology Limited | 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
PL210065B1 (pl) * | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
US7456171B2 (en) * | 2002-10-08 | 2008-11-25 | Sanofi-Aventis | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof |
FR2845388B1 (fr) | 2002-10-08 | 2004-11-12 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique |
AU2003283656A1 (en) | 2002-12-11 | 2004-06-30 | Pharmacia & Upjohn Company Llc | Combination for the treatment of adhd |
KR20050085535A (ko) | 2002-12-11 | 2005-08-29 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법 |
CA2513433A1 (en) * | 2003-01-22 | 2004-08-05 | Pharmacia & Upjohn Company Llc | Treatment of diseases with alpha-7 nach receptor full agonists |
US6945618B2 (en) | 2003-06-02 | 2005-09-20 | Accuride International Inc. | Drawer slide adjustment mechanism |
US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
-
2005
- 2005-03-25 AU AU2005227324A patent/AU2005227324A1/en not_active Abandoned
- 2005-03-25 BR BRPI0508771-6A patent/BRPI0508771A/pt not_active IP Right Cessation
- 2005-03-25 EP EP05745169A patent/EP1735306A2/en not_active Withdrawn
- 2005-03-25 SG SG200902028-0A patent/SG165199A1/en unknown
- 2005-03-25 EP EP10013706A patent/EP2336128A1/en not_active Withdrawn
- 2005-03-25 US US11/089,533 patent/US20050234095A1/en not_active Abandoned
- 2005-03-25 RU RU2006137472/04A patent/RU2417225C2/ru not_active IP Right Cessation
- 2005-03-25 JP JP2007505233A patent/JP4995075B2/ja not_active Expired - Fee Related
- 2005-03-25 NZ NZ550534A patent/NZ550534A/en not_active IP Right Cessation
- 2005-03-25 CN CN201310692588.7A patent/CN103724343A/zh active Pending
- 2005-03-25 KR KR1020067022085A patent/KR101176670B1/ko not_active IP Right Cessation
- 2005-03-25 MX MXPA06010852A patent/MXPA06010852A/es active IP Right Grant
- 2005-03-25 CA CA2560741A patent/CA2560741C/en not_active Expired - Fee Related
- 2005-03-25 WO PCT/US2005/010120 patent/WO2005092890A2/en active Application Filing
-
2006
- 2006-09-19 IL IL178188A patent/IL178188A/en not_active IP Right Cessation
- 2006-10-20 MA MA29406A patent/MA28972B1/fr unknown
- 2006-10-24 NO NO20064826A patent/NO20064826L/no not_active Application Discontinuation
- 2006-10-24 EC EC2006006951A patent/ECSP066951A/es unknown
- 2006-10-25 CR CR8711A patent/CR8711A/es unknown
-
2009
- 2009-12-04 US US12/631,435 patent/US8263619B2/en not_active Expired - Fee Related
-
2011
- 2011-06-21 US US13/165,370 patent/US8486937B2/en not_active Expired - Fee Related
- 2011-08-04 JP JP2011171124A patent/JP2011252002A/ja active Pending
-
2012
- 2012-01-09 CR CR20120010A patent/CR20120010A/es unknown
- 2012-03-18 IL IL218692A patent/IL218692A0/en unknown
-
2013
- 2013-03-15 US US13/838,088 patent/US8691841B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103724343A (zh) | 2014-04-16 |
IL178188A0 (en) | 2006-12-31 |
US20050234095A1 (en) | 2005-10-20 |
CA2560741A1 (en) | 2005-10-06 |
EP2336128A1 (en) | 2011-06-22 |
CR8711A (es) | 2007-08-28 |
JP4995075B2 (ja) | 2012-08-08 |
US8263619B2 (en) | 2012-09-11 |
CR20120010A (es) | 2012-02-13 |
NZ550534A (en) | 2009-07-31 |
EP1735306A2 (en) | 2006-12-27 |
WO2005092890A3 (en) | 2006-02-02 |
WO2005092890A2 (en) | 2005-10-06 |
SG165199A1 (en) | 2010-10-28 |
ECSP066951A (es) | 2006-12-20 |
AU2005227324A1 (en) | 2005-10-06 |
US20110319407A1 (en) | 2011-12-29 |
US8486937B2 (en) | 2013-07-16 |
US8691841B2 (en) | 2014-04-08 |
NO20064826L (no) | 2006-12-20 |
RU2006137472A (ru) | 2008-04-27 |
MXPA06010852A (es) | 2007-01-16 |
KR101176670B1 (ko) | 2012-08-23 |
RU2417225C2 (ru) | 2011-04-27 |
KR20070015406A (ko) | 2007-02-02 |
CA2560741C (en) | 2013-08-06 |
JP2011252002A (ja) | 2011-12-15 |
JP2007530590A (ja) | 2007-11-01 |
IL178188A (en) | 2012-10-31 |
IL218692A0 (en) | 2012-05-31 |
MA28972B1 (fr) | 2007-11-01 |
US20130217683A1 (en) | 2013-08-22 |
US20100105677A1 (en) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508771A (pt) | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos | |
BRPI0510212A (pt) | 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos | |
BRPI0417323A (pt) | indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos | |
BR0314485A (pt) | Indazóis, benzotiazóis e benzoisotiazóis, composto, composição farmacêutica, método desativação/estimulação seletiva de receptores nicotìnicos de a-7 em um mamìfero e método de tratamento e/ou prevenção de uma doença com os mesmos | |
SG165417A1 (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | |
DE602005024677D1 (de) | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen | |
MX2007007328A (es) | Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos. | |
GT200500307A (es) | Compuestos quimicos | |
BRPI0919876A8 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. | |
BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
ECSP099409A (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos | |
BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
EP2202222A3 (en) | Indene derivatives, their preparation and use as medicaments | |
PA8513801A1 (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo | |
DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
IS2164B (is) | ß2-adrenvirk viðtaka gerandefni | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
BRPI0809981A2 (pt) | Compostos, processo de fabricação destes, composição farmacêutica que os contém, método de tratamento e/ou prevenção de doenças que são associadas a modulação de receptores de sst subtipo 5 e uso dos compostos. | |
BRPI0811849A8 (pt) | composto, composição farmacêutica, e, métodos para preparar o composto e para tratar doenças ou condições mediadas por ccr1 | |
DE602004023946D1 (de) | Kombinationen aus einem arylanilin-beta-2-adrenozeptor-agonisten und einem corticosteroid | |
DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |